Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation

Hepatitis B Virus Associated Liver Disease Clinical Trial

Official title:

Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin Used in Combination With Lamivudine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01421212
• Other study ID #: Nabi-4204
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 1999
• Est. completion date: February 2002

Study information

• Verified date: August 2011
• Source: Biotest Pharmaceuticals Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find the best monthly dose schedule for the new Hepatitis Immune Globulin (Boca HBVIg, a study drug) when used in combination with an antiviral agent Lamivudine after liver transplantation. Boca HBVIg will be given along with Lamivudine to prevent hepatitis B reinfection following liver transplantation in patients with end stage liver failure due to hepatitis B infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: February 2002
• Est. primary completion date: February 2002
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be 18 years old or greater, either male or female, of any ethnic background.

• Be positive for HBsAg. Patients may be either positive or negative for anti-HDV, HBeAg, and HBV DNA (non-PCR assay).

• Be diagnosed with HBV-induced liver disease including either:

• HBsAg positive cirrhosis, or

• HBsAg positive and presence of hepatocellular carcinoma (HCC) with no evidence of vascular invasion or extrahepatic spread, and either:

• a single tumor no larger than 5 cm in diameter, or

• no more than three tumors, the largest of which is no greater than 3 cm in diameter.

• Have received at least one dose of Lamivudine 100 mgs po qd prior to transplantation.

• Fulfill UNOS minimal listing criteria.

• Have received approval for liver transplantation at the respective participating center and are listed as Status 2 or 3 and felt to be within three months of liver transplantation.

• If requiring retransplantation for primary graft nonfunction or hepatic artery thrombosis, retransplantation must take place within the first four weeks of the initial transplant with no evidence of recurrent hepatitis B.

• Be able and willing to give written informed consent. In patients with Grade 3 or 4 hepatic encephalopathy, a legal guardian must be available to provide consent. In the case of a minor, a parent or guardian must provide consent.

• If a woman of childbearing potential, have a negative serum beta HCG pregnancy test within 14 days prior to starting Lamivudine therapy and within 14 days prior to transplant and agree to practice contraception during the study (a total of 36 weeks).

Exclusion Criteria:

• Eligible patients must not:

• Require retransplantation for recurrent hepatitis B.

• Have chronic hepatitis B liver disease with a history of breakthrough infection on Lamivudine

• Have other causes of liver disease including chronic hepatitis C.

• Have HCC and do not meet Inclusion Criterion #3, or who require systemic chemotherapy.

• Be seropositive for HIV infection.

• Be using experimental devices or receiving experimental drugs.

• Be participating in any other clinical treatment trial with an investigational drug within 30 days prior to liver transplantation or plan to receive another investigational drug during this study.

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B Virus Associated Liver Disease
• Liver Diseases

Intervention

Biological:
• Hepatitis B Immune Globulin (Boca HBVIg)
Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses). Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study.

Locations

Country	Name	City	State
United States	The University of Michigan Health System	Ann Arbor	Michigan
United States	The University of North Carolina Hospitals	Chapel Hill	North Carolina
United States	Rush-Presbyterian - St. Luke's Medical Center	Chicago	Illinois
United States	University of Florida	Gainesville	Florida
United States	Mayo Clinic Jacksonville	Jacksonville	Florida
United States	Jackson Memorial Hospital / University of Miami	Miami	Florida
United States	Mount Sinai Medical Center	New York	New York
United States	New York-Presbyterian Hospital Columbia-Presbyterian Medical Center	New York	New York
United States	Medical College of Virginia Commenwealth University	Richmond	Virginia
United States	Rochester Methodist Hospital	Rochester	Minnesota
United States	University of California, San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Biotest Pharmaceuticals Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of hepatitis B virus positive liver transplant recipients with no hepatitis B virus recurrence after liver transplantation.
Primary	Number of participants who maintain a protective trough titer of anti hepatitis B antibodies beginning at 12 weeks post liver transplantation.
Secondary	Change in anti hepatitis B antibodies levels with administration of Boca hepatitis B immune globulin concomitantly with Lamivudine.